Search

for
Search:

GlossaryCetuximab

monoclonal antibody used to treat certain cancers by targeting EGFR

Cetuximab, also known by the brand name Erbitux, is a monoclonal antibody used in cancer treatment. It works by targeting the epidermal growth factor receptor (EGFR) on the surface of cancer cells, inhibiting their growth and survival. This drug is commonly used to treat certain types of head, neck, and colorectal cancers.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 184 results

research Histopathologic Features of Erythematous Papulopustular Eruption to Epidermal Growth Factor Receptor Inhibitors in Cancer Patients

9 citations , October 2015 in “Journal of Cutaneous Pathology”

Erythematous papulopustular eruptions in cancer patients using EGFR inhibitors show specific skin changes that vary with severity and treatment type.

research Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor

5 citations , April 2016 in “PubMed”

Cetuximab often causes skin problems, but they can be managed without stopping treatment.

research Trichomegaly of the Eyelashes Following Treatment with Cetuximab

78 citations , June 2005 in “Annals of oncology”

Cetuximab can cause excessive eyelash growth.

research Cetuximab-Induced Hypertrichosis of the Scalp and Eyelashes

12 citations , February 2010 in “Journal of The American Academy of Dermatology”

A cancer drug caused unusual hair growth on a 100-year-old man's scalp and eyelashes.

Cutaneous and Mucosal Side Effects of New Anticancer Drugs: EGF-R Inhibitors, Tyrosine Kinase Inhibitors, and Mitotic Spindle Stabilizers

research Cutaneous and Mucosal Side Effects of New Anticancer Drugs: EGF-R Inhibitors, Tyrosine Kinase Inhibitors, and Mitotic Spindle Stabilizers

January 2011

New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.

View more "cetuximab" in research →

Community Join

0 / 0 results

— no results